Journal of Cutaneous Immunology and Allergy最新文献

{"title":"A case of myasthenia gravis following alopecia areata","authors":"Naoki Sasaki MD,&nbsp;Yu Sawada MD, PhD","doi":"10.1002/cia2.12327","DOIUrl":"10.1002/cia2.12327","url":null,"abstract":"<p>We present a case of myasthenia gravis that occurred after alopecia areata and evaluate the literature on the comorbidity of alopecia and myasthenia gravis. A 41-year-old male noticed hair loss on his scalp 4 months ago, and his hair loss progressed with drooping of both upper eyelids and diplopia. Physical and laboratory examination identified the comorbidity of myasthenia gravis and alopecia areata. Prednisolone 10 mg/day and tacrolimus 3 mg/day were administered for 7 days following hospitalization, which served to improve diplopia and ptosis. Following methylprednisolone therapy, hair loss in alopecia areata improved without the enlargement of bald areas. Based on the literature review, a total of 29 cases with alopecia and myasthenia gravis including our case have been reported. Among them, seven cases of myasthenia gravis developed after alopecia. The average time for the onset of myasthenia gravis after alopecia was 16.6 months. Four cases showed other autoimmune disease comorbidity, such as vitiligo, lichen planus, cutaneous lupus erythematosus, and pemphigus foliaceus, suggesting the involvement of Th1-significant immunological states in these patients.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"237-240"},"PeriodicalIF":1.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The presence of neutrophil extracellular traps in different forms of pyoderma gangrenosum","authors":"Takaharu Ikeda MD, PhD,&nbsp;Tamihiro Kawakami MD, PhD,&nbsp;Kae Yokoyama MD,&nbsp;Yuka Nishibata PhD,&nbsp;Sakiko Masuda PhD,&nbsp;Utano Tomaru MD, PhD,&nbsp;Akihiro Ishizu MD, PhD","doi":"10.1002/cia2.12331","DOIUrl":"10.1002/cia2.12331","url":null,"abstract":"<p>We demonstrated that there were abundant neutrophil extracellular traps (NETs) in the skin biopsies from various types of pyoderma gangrenosum (PG), based on the observation of extended and compact areas of immunolabeling of MPO and Cit H3 proteins. We suggest that neutrophils could undergo an aberrant NET formation in the lesions of PG patients, in the vast majority of idiopathic PG. We did not detect NETs in the skin ulcers of an antiphospholipid syndrome patient with a similar appearance to classical ulcerative PG, while rich NETs were found in the various types of PG. These findings suggest that the presence of NETs in skin tissues could serve as a marker for making differential diagnoses of various types of PG from other similar conditions.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"241-244"},"PeriodicalIF":1.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135267519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolation of Shiga Toxin Producing Escherichia coli 0157:H7 from Environmental and Clinical Samples in Dhaka City","authors":"Samira Khandaker Shuvra","doi":"10.37191/mapsci-2582-6549-4(2)-045","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-4(2)-045","url":null,"abstract":"Escherichia coli O157:H7, a Shiga toxin producing microbe was first acknowledged as a virulent organism in 1982 during an analysis of an outbreak of haemorrhagic colitis associated with consumption of hamburgers from a fast-food chain restaurant. Ability of Escherichia coli O157:H7 to induce injury in humans is a result of its ability to produce numerous virulence factors, most notably Shiga toxins Stx1 and Stx2, both of which constitute one of the most potent toxins known to man. Besides, Shiga toxin, Escherichia coli O157:H7 produces several other virulence factors, which include proteins which aid in the attachment and colonization of the bacteria in the intestinal wall and which can break down red blood cells and release iron to help support metabolism in Escherichia coli . Virulence factors facilitate this organism’s ability to cause intestinal and extra-intestinal diseases such as diarrhoea, haemorrhagic colitis (HC), haemolytic uremic syndrome (HUS), urinary tract infections (UTI), septicaemia and neonatal meningitis. In this study r, 7 samples from Dhaka city was collected, cultured in various media for enumeration, isolation and screening of Escherichia coli colonies which were further analysed to check for the presence of stx genes using PCR and gel electrophoresis. The seven samples collected were: Door knob swab, tea water, bhel puri, kitchen pipe swab, vegetable water, Lake water and Skin swab. The samples collected initially were enriched in enrichment media overnight, followed by a dilution series which were then used for spread plating on nutrient agar and MacConkey agar and EMB for confirmation with the observation of pink colonies and metallic sheen. The confirmed Escherichia coli isolates were later subjected to DNA extraction and amplification after which the bands for stx genes were observed and recorded. Out of the seven samples tested for stx1 and stx2 genes, two showed the presence of stx1 genes and one showed the presence of stx2 gene. The presence of the stx1 and stx2 genes in regular food and in the surrounding signifies how close is a large outbreak. Knowledge of processing such food or avoiding such environmental contacts or taking precautions when possible may prevent occurrence of diseases.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135365547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early improvement of nailfold videocapillaroscopy abnormalities in dermatomyositis patients with anti-NXP-2 antibody","authors":"Naoki Mugii PhD,&nbsp;Yasuhito Hamaguchi MD, PhD,&nbsp;Natsumi Fushida MD,&nbsp;Motoki Horii MD, PhD,&nbsp;Tasuku Kitano MD,&nbsp;Ko Fujii MD,&nbsp;Kaori Sawada MD, PhD,&nbsp;Kyosuke Oishi MD, PhD,&nbsp;Shintaro Maeda MD, PhD,&nbsp;Takashi Matsushita MD, PhD","doi":"10.1002/cia2.12334","DOIUrl":"10.1002/cia2.12334","url":null,"abstract":"<p>This study aimed to evaluate long-term changes in nailfold videocapillaroscopy (NVC) findings in dermatomyositis patients with antinuclear matrix protein 2 (NXP-2) antibody (Ab). All four patients with anti-NXP-2 Ab presented irregularly enlarged and reduced capillaries and hemorrhages at the initial assessment. After disease stabilization, irregularly enlarged capillaries and hemorrhages disappeared within the mean observation period of 6 months. These early improvements were not observed in patients with anti-TIF1 Ab. The results of this study show that long-term changes in NVC findings should be assessed using myositis-specific Ab information.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"245-248"},"PeriodicalIF":1.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135918298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of upadacitinib in Japanese patients with prurigo-type atopic dermatitis: Four cases report","authors":"Keiji Kosaka MD,&nbsp;Akihiko Uchiyama MD, PhD,&nbsp;Mai Ishikawa MD,&nbsp;Sei-ichiro Motegi MD, PhD","doi":"10.1002/cia2.12333","DOIUrl":"10.1002/cia2.12333","url":null,"abstract":"&lt;p&gt;Prurigo-type atopic dermatitis (AD) is an AD variant characterized by excoriated papules, indurated nodules, and intense itching associated with type 2 cytokine responses.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Recently, upadacitinib, an oral selective Janus kinase (JAK) 1 inhibitor, was found to be efficacious and safe in treating moderate-to-severe AD in patients aged &gt;12 years in a clinical trial.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; However, few reports have demonstrated evidence of upadacitinib in prurigo-type AD. Here, we present four Japanese patients with prurigo-type AD who received upadacitinib.&lt;/p&gt;&lt;p&gt;Our cases included two male and two female patients with moderate-to-severe AD (Table S1). The patients fulfilled the AD criteria.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Cases 3 and 4 were also confirmed AD pathologically. They were treated with 15 or 30 mg upadacitinib, topical corticosteroid, and moisturizers once a day. Case 1: a 49-year-old female with widespread areas of erythema, nodules, and itching on her legs (Figure 1A). We initiated 30 mg of upadacitinib. After 8 weeks, she achieved Eczema Area and Severity Index (EASI)-90 and was itch-free (Figure 1B). Case 2: a 50-year-old female. She applied corticosteroid ointments on her refractory nodules for decades (Figure 1C). She had difficulty throughout her life due to insomnia caused by itching. We initiated 30 mg of upadacitinib; she was pruritus-free after 2 weeks, achieving EASI-90 after 4 weeks (Figure 1D). Case 3: a 64-year-old male with multiple pruritic nodules on his trunk and extremities (Figure 1E). We first initiated 30 mg of upadacitinib for his severe itchiness. After 4 weeks, his skin lesions and itching improved noticeably. Thus, we decreased the upadacitinib dose to 15 mg. After 12 weeks, his skin lesions almost disappeared (Figure 1F). Case 4: a 66-year-old male. He had multiple nodules on his neck and arms, forming plaque (Figure 1G). Although we diagnosed him with severe AD, we prescribed 15 mg of upadacitinib because of his age. After 12 weeks, he achieved EASI-90, and his skin lesions almost disappeared (Figure 1H). No adverse events were observed in the patients.&lt;/p&gt;&lt;p&gt;Figure 1I–K shows the transition of EASI, patient-oriented eczema measure (POEM), and pruritus numerical rating scale (NRS). A rapid decrease was seen in all categories from baseline to Week 4, and this effectiveness lasted for 12 weeks. Thymus and activation-regulated chemokine and immunoglobulin E in the serum were decreased from baseline to Week 4; however, some cases increased at Week 12 (Figure 1L,M).&lt;/p&gt;&lt;p&gt;The effectiveness of dupilumab and baricitinib against prurigo-type AD was recently reported.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; Dupilumab showed a significantly lower achievement rate of EASI-50 at 2 months in the prurigo compared with the non-prurigo group.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; These results indicate the importance of suppressing not only IL-4 and IL-13 but also other cytokines, including IL-31 and thymic stromal lymphopoi","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"262-263"},"PeriodicalIF":1.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135146754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonbullous pemphigoid representing clinical manifestation as eczematous skin eruption","authors":"Noriko Kagawa MD,&nbsp;Kayo Yamamoto MD,&nbsp;Eri Ohta MD,&nbsp;Yoko Akamatsu MD,&nbsp;Etsuko Okada MD, PhD,&nbsp;Yu Sawada MD, PhD","doi":"10.1002/cia2.12322","DOIUrl":"10.1002/cia2.12322","url":null,"abstract":"<p>Bullous pemphigoid (BP) is a representative autoimmune subepidermal blister disease, and approximately 20% of cases recognized the absence of a typical blister. Those cases result in delayed diagnosis and appropriate therapeutic selection results, leading to an increased mortality rate. Herein, we present a case of initial misdiagnosed as persistent eczematous eruption, which was finally confirmed as nonbullous pemphigoid by repeated histological examinations\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"251-252"},"PeriodicalIF":1.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135645570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pityriasis rubra pilaris following administration of SARS-CoV-2 vaccine","authors":"Shumpei Kondo MD,&nbsp;Yasuaki Ogura MD,&nbsp;Masaki Ohtsuka MD, PhD,&nbsp;Yoshiki Tokura MD, PhD","doi":"10.1002/cia2.12326","DOIUrl":"10.1002/cia2.12326","url":null,"abstract":"<p>Pityriasis rubra pilaris (PRP) is a rare, chronic, inflammatory dermatosis characterized by follicular, hyperkeratotic papules and palmoplantar keratoderma at any age. The exact etiology of the disease remains unknown, but it can be triggered by multiple factors and genetic backgrounds. Here, we describe a case of PRP occurring after SARS-CoV-2 vaccination. While the vaccination is generally safe, it should be kept in mind that PRP may be evoked by SARS-CoV-2 vaccination for early recognition of the cause and prognosis of the patients.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"234-236"},"PeriodicalIF":1.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135738912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased CXCL14 expression in psoriasis recovered by narrow-band ultraviolet B therapy","authors":"Kaori Nakajima MD,&nbsp;Tomomitsu Miyagaki MD, PhD,&nbsp;Miho Tanaka MD,&nbsp;Reo Komaki MD,&nbsp;Tatsuro Okano MD, PhD,&nbsp;Sora Takeuchi MD, PhD,&nbsp;Hidenori Watabe MD, PhD,&nbsp;Takafumi Kadono MD, PhD","doi":"10.1002/cia2.12332","DOIUrl":"10.1002/cia2.12332","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>CXCL14 is a member of CXC chemokine family, constitutively expressed in various normal tissues unlike many other chemokines. Other than the capacity to recruit natural killer cells, macrophages, and dendritic cells, CXCL14 suppresses CXCL12-CXCR4 interactions by inducing CXCR4 internalization. Thus, CXCL14 can both promote and hinder immune responses. Psoriasis is a chronic skin inflammatory disorder in which various chemokines play an important role.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To investigate possible roles of CXCL14 in psoriasis, we examined CXCL14 expression in lesional skin by immunohistochemistry and measured serum CXCL14 levels in psoriasis. We also assessed the effect of ultraviolet irradiation, one of the main therapies for psoriasis, on CXCL14 expression by HaCaT cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CXCL14 expression was decreased in epidermal keratinocytes in lesional skin and serum CXCL14 levels were negatively correlated with Psoriasis Area and Severity Index scores in psoriasis patients. Serum CXCL14 levels were increased in nbUVB-treated psoriasis patients and UVB irradiation induced CXCL14 mRNA expression from HaCaT cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results suggest that decreased CXCL14 expression may contribute to the exacerbation of psoriasis and that the amplification of CXCL14 can be a therapeutic option for psoriasis. One of the mechanisms of the efficacy of nbUVB therapy in psoriasis may be the upregulation of CXCL14.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"225-230"},"PeriodicalIF":1.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in patient-perceived aggravating factors during the course of atopic dermatitis","authors":"Nozomi Yanagida MD,&nbsp;Ryo Saito MD, PhD,&nbsp;Akiko Kamegashira MD, PhD,&nbsp;Satoshi Morioke MD, PhD,&nbsp;Akio Tanaka MD, PhD","doi":"10.1002/cia2.12329","DOIUrl":"10.1002/cia2.12329","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to clarify how patient-perceived aggravating factors change during the course of AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study involved a questionnaire-based survey administered to 115 patients with AD at our hospital. The changes in patient-perceived aggravating factors were examined as treatment progressed by readministering the questionnaire to 36 patients 6 months later.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The most frequent aggravating factors at the first visit were sweating, emotional stress, and house dust. The number of patients who identified food, dust mites, house dust, pollen, and pets as aggravating factors decreased during the course of the disease. However, the number of patients who identified sweating, environmental factors, emotional stress, and lack of sleep as aggravating factors did not differ from those at the first visit; this included those who newly identified these as aggravating factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Many patients with AD are concerned about the aggravating factors, and it may be possible to reduce aggravating factor-related anxiety by informing patients that certain aggravating factors may change during treatment. Hence, it is necessary to ask patients about the aggravating factors at the first visit and fixed intervals and resolve them immediately.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"219-224"},"PeriodicalIF":1.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135244619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brentuximab vedotin treatment for mycosis fungoides with CD30+ large-cell transformation in the early stage","authors":"Shujiro Hayashi MD, PhD,&nbsp;Shown Tokoro MD,&nbsp;Ken Igawa MD, PhD","doi":"10.1002/cia2.12330","DOIUrl":"10.1002/cia2.12330","url":null,"abstract":"&lt;p&gt;Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, is characterized by the proliferation of small- to medium-sized atypical, usually CD4+ T cells in the skin.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Mycosis fungoides with large-cell transformation (LCT) is an aggressive subtype defined by the presence of large cells comprising &gt;25% of the lesion infiltrate or the presence of microscopic nodules of large cells. Large-cell transformation occurs in 20%–55% of advanced MF cases and is often a histological marker of poor prognosis and is associated with a mean 5-year survival rate of &lt;20%.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Herein, we present a patient with MF-LCT in its early stage that was successfully treated with brentuximab vedotin (BV), an anti-CD30 antibody.&lt;/p&gt;&lt;p&gt;A woman in her early 30s had erythema with pruritus and pigmentation on her trunk and thighs for 3 years (Figure 1A). Following subsequent histopathological diagnosis as MF (negative CD30+ lymphocytes at this time), she was successfully treated with topical steroids and ultraviolet therapy and showed no progression for approximately 10 years. In her early 40s, the rash slowly expanded and was treated with bexarotene (450–150 mg/day). One year later, the eruption intensified, with erythema observed on 40% of the body and multiple skin tumors of ≥1 cm (Figure 1B,C). Histopathology and immunohistochemistry of the tumors confirmed infiltration with CD3+, CD4+, CD5+, CD8+ (CD4/CD8: 10/1), CD30+, and CD20− lymphocytes, and CD30+ lymphocytes with large nuclei comprised 30% of the infiltrate (Figure 1D,E). The patient's complete blood count was normal, and the peripheral blood smear was negative for Sézary cells. Bone marrow examination showed no infiltration of atypical lymphocytes. No lymph node metastasis was found on positron emission tomography–computed tomography. Mycosis fungoides stage IIB (T3M0N0) with CD30+ LCT was diagnosed, and BV treatment was initiated instead of bexarotene. After three doses, the eruption area decreased, and the nodules became flattened (Figure 1E,F). After a total of 16 BV treatments, the only side effect observed was mild sensory polyneuropathy.&lt;/p&gt;&lt;p&gt;Brentuximab vedotin is an antibody–drug conjugate (ADC) in which monomethyl auristatin E (MMAE), which has cytotoxic activity, and an anti-CD30 IgG1-type chimeric antibody are linked via a protease-cleavable linker. The ADC inhibits tumor growth by first binding to CD30+ cells. Then, after being taken up into the cells as an ADC–CD30 complex, it releases MMAE through a proteolytic reaction. The free MMAE further inhibits microtubule formation and induces cell cycle arrest and apoptosis.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In a clinical trial of 30 patients (MF and Sézary syndrome), the response rate for BV was 70%, wherein 54% of the respondents were free of disease progression for 1 year&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;; however, the information on MF-LCT is still limited.&lt;/p&gt;&lt;p&gt;Bhari N et al. reported that the survival p","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 6","pages":"260-261"},"PeriodicalIF":1.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135246702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}